Basilea announces change in its management structure
Ronald Scott was appointed Chief Financial Officer at the company's inception. In addition to finance, business development, investor relations and public relations, he now assumes responsibility for commercial activities, manufacturing and corporate services with the respective departments retaining their heads. He will continue as ad interim Chief Financial Officer. In line with Basilea's strategic focus to bring innovative new drugs to the market, research and development, including Basilea's operations in China, will continue to report directly to Chief Executive Officer, Dr. Anthony Man.
Most read news
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.